Eli Lilly & Co. (LLY) Reports Interim Results for MONARCH 3 Study Highlighting Benefit of Verzenio (Abemaciclib) Plus NSAI in Advanced Breast Cancer
Tweet Send to a Friend
Eli Lilly and Company (NYSE: LLY) today announced that interim results from the double-blind, placebo-controlled Phase 3 MONARCH 3 study ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
